Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT7O8R
|
|||
| Drug Name |
Tavokinogene telseplasmid
|
|||
| Synonyms |
TAVO
Click to Show/Hide
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1], [2] | |
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | ||
| Company |
OncoSec Medical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukine 12 (IL-12) | Target Info | Replacement | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.